When Two Experts Tell You Different Things
You went to two specialists and received conflicting treatment recommendations.
Many families face this after a glioblastoma diagnosis. It can be very confusing. When experts disagree, what should that tell you? And what can you do about it?
The answer is in the tumor's biology. Glioblastoma isn't a single disease. Two tumors with the same diagnosis can have different genetic changes. These changes affect how tumors respond to treatment. When specialists disagree, they're usually working with incomplete information about what's driving that specific tumor. More detailed genetic testing can provide clearer answers.
Why Glioblastoma Experts Sometimes Reach Different Conclusions
When neuro-oncologists disagree, it's not because one is careless. They use the same medical evidence and training, but they interpret it differently when test results have gaps.
The core problem is this: looking at tumor tissue under a microscope shows what the tumor looks like. It doesn't show what's driving the tumor's behavior at the genetic level.
Two tumors that look identical under a microscope can have very different genetic changes that lead to different behaviors and outcomes. These differences matter for treatment decisions.
When specialists have incomplete genetic data, they can reach different conclusions that are both reasonable. Their disagreement means you should investigate further, not just pick one side.
What the Standard Diagnostic Report Often Cannot Reveal
The standard genetic tests for newly diagnosed glioblastoma typically include:
- Histopathology and tumor grade
- IDH mutation status
- MGMT promoter methylation status
- ATRX status and 1p/19q codeletion (usually to rule out other glioma types)
These markers matter. MGMT promoter methylation is one of the most important predictors of how the tumor responds to temozolomide chemotherapy, which is standard treatment. IDH status helps confirm the diagnosis and classify the tumor correctly under current WHO guidelines.
But the standard panel doesn't capture the full genetic picture. Research shows that next-generation sequencing can find changes—including EGFR amplification, PTEN loss, CDKN2A/B deletion, TERT promoter mutations, and high tumor mutational burden—that may be relevant to clinical trial eligibility and treatment selection.
The standard report is just a starting point. For many patients, especially those getting conflicting advice, it may not be enough to answer the most important questions.
For a detailed overview of which tests are recommended and when, our guide on what molecular tests your newly diagnosed glioblastoma actually needs walks through the complete landscape.
Tumor Heterogeneity: The Biological Reason Opinions Diverge
Glioblastoma isn't a mass of identical cells. It's a collection of genetically different cell populations. This is called intratumoral heterogeneity.
Research has confirmed that different regions of the same tumor can carry different genetic profiles. A tissue sample from one area may not represent what's happening elsewhere. The standard report is based on tissue from one sample location, so it may miss genetic changes that are present in other parts of the tumor and may be affecting how the tumor resists treatment or behaves overall.
This helps explain why two specialists can reach different conclusions from the same report. Each is reasoning correctly from the data they have. But the data may be incomplete. Each expert fills in the gaps based on their own experience. Understanding this doesn't instantly solve the conflict. But it shows why more detailed genetic analysis is often the best way to get better information.
How Molecular Profiling May Help with Contradictory Recommendations
Molecular profiling is a type of tumor testing designed to map the genetic features of a glioblastoma in more detail than standard tests allow. It may include:
- Whole Exome Sequencing (WES): Reads the protein-coding regions of the tumor's genes to find mutations, deletions, and amplifications across thousands of genes.
- RNA Sequencing: Shows which genes the tumor is actively using, revealing active signaling pathways that may not be visible at the DNA level alone.
- Methylation profiling: Maps chemical changes across the genome that can classify the tumor more precisely and sometimes reveal a different diagnosis than tissue examination alone suggested.
- Drug sensitivity analysis: Uses the tumor's genetic profile to identify which treatments may work against that specific tumor's biology.
A pilot study on personalizing glioblastoma treatment using whole exome sequencing found that this approach could identify actionable genetic changes not detected through standard clinical testing, with potential implications for treatment selection and individualized planning.
When a patient receives contradictory expert recommendations, a more detailed genetic profile may clarify which biological features the tumor actually has. The goal isn't to override the oncologist's judgment. It's to give that judgment more solid information to work with.
For guidance on understanding what your genetic report actually contains once testing is complete, see our article on interpreting your glioblastoma genetic report: genetic mutations, pathways, and personalized drug selection.
Biological Vulnerabilities That Extended Profiling May Surface
One key reason more detailed genetic profiling can help resolve conflicting opinions is that it may reveal specific biological weak points in the tumor. These weak points aren't visible on the standard report and may change how specialists think about treatment.
Some examples of what extended profiling may identify:
- MGMT methylation status that is unclear on standard testing, clarified by quantitative analysis methods
- EGFR amplification or EGFRvIII variant status, which may affect eligibility for certain clinical trials
- PTEN loss, which can affect signaling pathways relevant to treatment selection and how the tumor resists therapy
- High tumor mutational burden (TMB), which may indicate potential response to immunotherapy approaches currently under investigation
- BRAF V600E mutation, for which FDA-approved treatments with demonstrated activity in some tumor types exist
- TERT promoter mutation patterns, which help confirm IDH-wildtype glioblastoma classification and may relate to clinical behavior
Research on precision neuro-oncology in recurrent glioma found that patients treated with treatments matched to their tumor's genetics showed longer progression-free and overall survival compared to those without genetic matching, though the evidence is still developing and results vary across different patient groups. These findings suggest that identifying specific weak points through extended profiling may open treatment options that a standard diagnostic panel would not have identified.
These findings don't guarantee results. Glioblastoma remains one of the hardest cancers to treat. But specific genetic findings may open possibilities—clinical trials, off-label treatments, additional strategies—that would otherwise be missed in a standard clinical consultation.
What International Patients Need to Know
Families in major medical centers around the world who are dealing with conflicting expert advice often find the same thing: their local team is giving the best guidance possible with the available test results. But those test results may be the limiting factor.
Location doesn't limit access to genetic expertise. Reports can be reviewed remotely. MRI scans in DICOM format can be reviewed digitally. Pathology slides and genetic test results can be interpreted by specialist teams without the patient needing to travel. Initial consultations with precision-oncology experts can happen by video from any location.
This means families can request a remote tumor review and have their existing reports, imaging, and genetic results assessed by a team with specific expertise in glioblastoma biology. Expertise in glioblastoma genetic medicine matters more than physical proximity to a clinic.
A detailed review of pathology and imaging may reveal insights worth discussing with your care team. Many families begin with a virtual consultation and a report review before deciding on next steps. You can learn more about how this works in our guide on getting a glioblastoma second opinion remotely: how remote genetic assessment and virtual expert consultation work.
What Reports Should You Gather Before Seeking an Expert Review?
Before requesting a precision-oncology consultation or tumor intelligence review, gather as many of these as possible:
- Pathology Report — the initial diagnosis and any neuropathology consultation reports
- Histopathology Report — including tumor grade, cell morphology, and immunohistochemistry results
- MRI Brain Reports — pre-surgical, post-surgical, and most recent follow-up scans (DICOM files are preferable to printed images or PDFs)
- Surgical Notes — operative reports detailing resection extent, tumor location, and intraoperative findings
- Genetic Testing Results — MGMT methylation, IDH mutation, EGFR, PTEN, TERT, and any next-generation sequencing panels already completed
- Current Treatment Plan — details of ongoing or planned chemotherapy, radiation, or adjunct therapies
- Previous Treatment History — prior lines of therapy, doses, and clinical response
A complete picture allows a reviewing expert to make the most useful assessment. If some documents are missing, it's worth starting anyway. Gaps can be addressed as results arrive. Many families begin with what they have and build the complete picture over time. Understanding your tumor's biology may help guide better discussions with your doctors at every stage.
Common Mistakes After Receiving Conflicting Advice
When specialists disagree, families often make decisions that can slow progress or be based on incomplete genetic data.
Choosing based on hope instead of data. It's natural to favor the option that sounds most promising. But if one recommendation is based on more detailed genetic data than another, the data-supported direction may deserve more weight, regardless of which answer feels more hopeful right now.
Waiting too long for the conflict to resolve. Glioblastoma moves quickly. Long delays can use up treatment options that are harder to access later. A third expert opinion grounded in deeper genetic analysis is often the fastest way to a clear direction.
Assuming all genetic reports are equally complete. A standard MGMT and IDH panel and a whole exome sequencing result are very different. One may surface a clear finding while the other reveals something the first missed. Not all genetic testing covers the same depth.
Not asking the right questions. When experts disagree, ask each directly: what specific data is your recommendation based on? What additional information would change your advice? These questions often show exactly what gaps deeper testing can fill.
Questions to Ask Your Oncology Team
These questions may help you talk with your doctors after receiving conflicting recommendations:
- What specific genetic data is your recommendation based on?
- Has this tumor been tested beyond the standard MGMT and IDH panel?
- Are there genetic changes this report may have missed that would change your approach?
- Would whole exome sequencing or RNA sequencing add helpful information in my case?
- Are there clinical trials I might qualify for if additional genetic changes were found?
- Would you work with a precision-oncology team that could review the genetic data with you?
- How would additional testing results change the treatment plan you're recommending?
When to Talk to Your Doctor
Talk to your neuro-oncologist or treating team if:
- You have received conflicting treatment recommendations and aren't sure how to evaluate them
- You want to know whether additional genetic testing has been ordered or could be requested
- You are considering a second or third expert opinion that includes genetic analysis
- You want to understand whether your current test results are sufficient for the treatment decisions ahead
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.